A negative predictive value of 99% for a non-invasive test makes it very hard to justify having an invasive procedure as the initial investigation - especially when it can be done outside the clinic environment. And its lower specificity means urologists will still see enough cystoscopies in clinical practice to keep them happy and more importantly not objecting. In all honesty, unless there are more sinister motivations in play, the new guidelines should support CxBladder's inclusion.
From a share price perspective, I suspect there will be some selling / consolidation soon. People have long memories and the previous CEOs divestiture and retirement, capital raise and Novitas meeting all within a short space of time has left a bad taste that will require a stiff dose of positive results to get fully rid of. More than a few will recoup losses, get out and never return.
PEB Price at posting:
16.0¢ Sentiment: Buy Disclosure: Held
